September 2011

Advances in the understanding of tumor biology and a robust drug development pipeline are combining to form a 'perfect storm' of opportunity for personalized cancer research to make a leap forward.

An interview with Neal D. Shore, MD, discussing expanding the scope of cystoscopy and the optical imaging agent Cysview.

Improving the accuracy and value of tumor marker testing in patients with breast cancer has resulted in a dramatic upswing in accredited laboratories and the clarification of guideline definitions.

Nita Maihle, PhD, is a professor of Obstetrics, Gynecology and Reproductive Sciences, and director of a clinically oriented cancer research laboratory at Yale University, New Haven, Connecticut.

Roy S. Herbst, MD, PhD, is a physician and translational researcher, whose work in developing novel, personalized therapies for lung cancer has helped drive significant changes in the way the disease is treated.

The epidermal growth factor receptor (EGFR) is the prototypical receptor tyrosine kinase (RTK) and one of the most comprehensively studied molecular targets in clinical oncology.

This report highlights 5 abstracts relevant to the current and future management of patients with female pelvic malignancies.

The desire to reduce the risk and severity of treatment-related toxicity by rapidly discontinuing ineffective therapy, and the increasing use of highly sensitive imaging technology.